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†Department of Physiology and Biophysics and ‡Department of Chemistry, Case Western Reserve University, Cleveland, OhioABSTRACT Efavirenz is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) and a common compo-
nent of clinically approved anti-AIDS regimens. NNRTIs are noncompetitive inhibitors that bind in a hydrophobic pocket in the
p66 subunit of reverse transcriptase (RT) ~10 A˚ from the polymerase active site. Hydrogen exchange mass spectrometry
(HXMS) shows that efavirenz binding reduces molecular flexibility in multiple regions of RT heterodimer in addition to the NNRTI
binding site. Of the 47 peptic fragments monitored by HXMS, 15 showed significantly altered H/D exchange rates in the presence
of efavirenz. The slow cooperative unfolding of a b-sheet in the NNRTI binding pocket, which was previously observed in unli-
ganded RT, is dramatically suppressed by efavirenz. HXMS also defines an extensive network of allosterically coupled sites,
including four distinct regions of allosteric stabilization, and one region of allosteric destabilization. The effects of efavirenz
binding extend >60 A˚ from the NNRTI binding pocket. Allosteric changes to the structural dynamics propagate to the thumb
and connection subdomains and RNase H domain of the p66 subunit as well as the thumb and palm subdomains of the p51
subunit. These allosteric regions may represent potential new drug targets.INTRODUCTIONHIV-1 reverse transcriptase (RT) is an essential enzyme in
the HIV lifecycle and a major drug target. RT is a hetero-
dimer of 66 and 51 kDa subunits (Fig. 1 A). The p66 subunit
consists of a polymerase domain, containing fingers, palm,
thumb, and connection subdomains, and an RNase H
domain. In addition to the polymerase and RNase H active
sites (1), the p66 subunit contains most of the residues
that contact the primer/template (P/T) substrate. The poly-
merase and RNase H primer grips in p66 are important
structural motifs that position the nucleic acid substrate at
the enzyme active sites (1–3). The p51 subunit is identical
in sequence to the p66 polymerase domain, but lacks the
C-terminal RNase H domain. Despite a common amino-acid
sequence, p51 and p66 adopt different tertiary folds in
crystal structures of RT heterodimer.
Nonnucleoside RT inhibitors (NNRTIs) are an important
component of antiretroviral therapy. NNRTIs and protease
inhibitors are more potent inhibitors of viral replication
than nucleoside RT inhibitors (NRTIs) and integrase inhib-
itors (4). Using a mass-action-based model, Shen et al. (4)
found that the steep dose-response curves of NNRTIs and
protease inhibitors in single-round infectivity assays could
be explained by the fact that these drugs target the enzymes
themselves rather than specific enzyme-substrate
complexes. For example, NNRTIs can bind to and inhibit
multiple forms of RT, unlike NRTIs that target a single
RT-P/T complex in the process of catalyzing nucleotide
addition. This is supported by the observation that the
NNRTI nevirapine interferes with proper positioning ofSubmitted September 22, 2010, and accepted for publication November 3,
2010.
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0006-3495/11/01/0144/10 $2.00RT on P/T substrate in the absence of dNTP (5,6). Accumu-
lating evidence indicates that NNRTIs interfere with
multiple RT functions in addition to nucleotide addition,
and some NNRTIs may even disrupt later steps in the viral
life cycle, such as Gag-Pol processing (7).
NNRTIs are small hydrophobic compounds that bind to
a small pocket at the base of the thumb in the p66 palm
and allosterically inhibit polymerase activity (8). However,
the nature and extent of allostery in RT is not well defined.
Unlike regulatory sites in allosteric enzymes, the NNRTI
binding pocket does not appear to play a role in RT function.
In fact, the binding pocket is not present in crystal structures
of RT in the absence of bound NNRTIs (1,9,10). Crystal
structures of RT-NNRTI complexes indicate that formation
of the binding pocket is accompanied by further structural
changes, most notably an extended conformation of the
p66 fingers and thumb relative to unliganded RT (11).
X-ray crystallography and computer simulations suggest
that NNRTIs may function by restricting molecular motions
(2,12–15). Various inhibition mechanisms have been
proposed, including an arthritic thumb model, a primer
grip model, and an active site distortion model.
Recent studies suggest that RT binds NNRTIs by
a selected-fit binding mechanism (16–18). According to the
population shift model, a protein samples a wide ensemble
of states, only a small fraction of which is capable of binding
ligand. The presence of a ligand stabilizes the binding
competent states, which become the dominant population.
The current view of allosteric transitions in proteins posits
a population shift in either protein conformation, dynamics,
or both (19). In the past, allosteric communication was
thought to occur via a discrete pathway. The view of allostery
has evolved to encompass multiple pathways and conforma-
tional fluctuations. In the former, allosteric communicationdoi: 10.1016/j.bpj.2010.11.004
FIGURE 1 (A) Crystal structure of RT-EFV complex (1IKW). Four sub-
domains of the polymerase domain in p66 and p51 subunits: (blue) fingers,
(red) palm, (green) thumb, and (orange) connection. Faded colors indicate
subdomains of p51 subunit. The RNase H domain of p66 subunit is shown
in magenta. Balls show: (black) efavirenz; (pink) polymerase and RNase H
active sites; and (cyan) polymerase and RNase H primer grips. (B) Allo-
steric network in RT. Balls show: (dark blue) efavirenz binding region;
(cyan) region 1; (magenta) region 2; (green) region 3; (orange) region 4;
(yellow) region 5. (pale blue) Peptides with the same H/D exchange in pres-
ence and absence of efavirenz and (white) missing coverage. Figure made
using PyMOL (52).
Allosteric Network in Reverse Transcriptase 145occurs through changes in structure or dynamics along
a series of continuous pathways (20), whereas in the latter,
allostery arises by energetic coupling of intramolecular inter-
actions and protein-solvent interactions (21).
Hydrogen/deuterium exchange is a powerful method for
probing conformational fluctuations in proteins (22). Amide
hydrogens in stable hydrogen bonds or buried in the protein
interior are protected from exchange, but structural fluctua-
tions can transiently disrupt local structure, exposing these
protected hydrogens for exchange,
ClosedðHÞ%k1
k1
OpenðHÞ/kint OpenðDÞ%k1
k1
ClosedðDÞ;where k1 and k1 are the rate constants for the local unfold-
ing/refolding that exposes protected amides from exchange
and kint is the intrinsic, chemical rate of H/D exchange at
the given conditions. Interpretation of measured exchange
rates depends on the relative magnitudes of kint and k1.
When kint<< k1, exchange occurs by the EX2 mechanism;
the observed rate of exchange can be expressed as kobs ¼
(k1/k1)kint ¼ Kunf kint. Under these conditions, locally or
globally unfolded states are visited transiently, and refolding
is fast compared to the chemical rate of exchange. Thus un-
folding/refolding will typically occur many times before
a particular hydrogen exchanges with deuterium and the
observed rate of exchange is proportional to an equilibrium
constant for local (or global) unfolding, Kunf. When kint >>
k1, then exchange occurs by the EX1 mechanism and the
observed rate of exchange is a direct measure of the rate
of unfolding; kobs ¼ k1.
H/D exchange measured using mass spectrometry
(HXMS) provides exchange rates at the peptide level rather
than at the level of individual amide hydrogens (22). Upon
quenching exchange by decreasing pH, proteins are digested
with the acid protease pepsin, and the overall degree of
exchange in each peptic fragment (typically 5–20 residues)
is obtained from the mass. In the case of EX1 exchange, all
amide hydrogens in a given region exchange when that
region unfolds. If unfolding is slow (t1/2 > 1 s), this leads
to characteristic bimodal isotopic envelopes in the mass
spectra of peptides from that region, with the relative areas
of the upper and lower mass/charge ratio (m/z) peaks
corresponding to the populations in solution that have
sampled the unfolded state (upper m/z peak) or remained
folded (lower m/z peak). Under physiological conditions
in the absence of denaturants, such double isotopic enve-
lopes are rare but have been observed (23). Because the
p51 subunit has the same amino-acid sequence as the
polymerase domain of the p66 subunit, the subunits were
separated after H/D exchange but before peptic digestion
and analyzed in separate experiments by HPLC-MS. As
a result, any double isotopic envelopes observed in these
experiments are not artifacts due to different H/D exchange
behavior in the two subunits.
Previously, we used HXMS to study the structure and
dynamics of RT in solution (24). The HXMS studies of
RT heterodimer showed that the structure of the palm,
thumb, and connection subdomains of both subunits and
the RNase H domain of p66 are significantly more flexible
than expected from the crystal structure. An especially
tantalizing finding was that b-sheet b12-b13-b14, which
forms part of the binding pocket in the presence of NNRTI,
undergoes EX1 exchange. This behavior is due to slow
cooperative unfolding/refolding with t1/2 for unfolding
~20 s in the absence of NNRTI. The present work employs
HXMS to probe the structure and dynamics of RT bound to
efavirenz (EFV), a second generation NNRTI in clinical use.
The functional implications are discussed.Biophysical Journal 100(1) 144–153
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All biological reagents and chemicals were acquired from Roche Applied
Science (Indianapolis, IN) and Sigma Chemicals (St. Louis, MO) unless
otherwise specified. Efavirenz was obtained from the National Institutes
of Health AIDS Research and Reference Reagent Program (Germantown,
MD). D2O was purchased from Cambridge Isotope Laboratories (Andover,
MA). RT buffer D is 0.05 M Tris (RNase, DNase-free, pH 7.0), 25 mM
NaCl, 1 mM ethylenediaminetetraacetic acid, and 10% (v/v) glycerol
(molecular biology grade redistilled).
The p66 and p51 proteins with N-terminal hexahistidine extensions were
prepared separately as described (24,25). Proteins were expressed in
Escherichia coli and purified by column chromatography; protein concen-
trations (monomer units) were determined by absorbance at 280 nm (25).
The N-terminus of each monomer was labeled with biotin (24). The
p66/p51 heterodimer was formed by equilibrating one unlabeled monomer
with the other labeled monomer at 1:1 or 1:1.5 molar ratio in RT buffer D
containing 50% (v/v) glycerol for one week at 4C. The equilibrated protein
was dialyzed into 3 0.5–1L of RT buffer D containing 25mMefavirenz for
three days at 4C. The concentration of RT-EFV complex is calculated using
the Kd values for homo- and heterodimerization in the absence and presence
of efavirenz and the Kd values for efavirenz binding to monomers, homo-
dimers, and heterodimer (16,25). Solutions of 20–30 mM RT-EFV complex
(1:1 p66:p51, [EFV]¼ 25 mM) contain 84% p66/p51-EFV complex plus 6%
p66/p66-, 5% p51/p51-, 2% p66-, and 3% p51-EFV complexes. In
20–30 mM solutions of RT-EFV complex with 1.5-fold excess of labeled
subunit, the unlabeled subunit is driven to 97% p66/p51-EFV complex
with <3% homodimer- and monomer-EFV complexes.HXMS
Peptide-mapping experiments were conducted on a LTQ-Fourier transform
ion cyclotron resonance (FT-ICR) mass spectrometer (ThermoElectron,
Waltham, MA) to confirm peptide identification by exact mass (24).
HXMS experiments were performed as described previously (24,26).
A 20–30 mM solution of RT-EFV complex was diluted 10-fold into RT
buffer D-D2O containing 5% glycerol (v/v) and incubated for 10 different
times ranging from 5 s to 8 h at 25C. Exchangewas quenched by sevenfold
dilution into 100 mM NaH2PO4 (pH 2.4) containing 100 mL of Ultralink
immobilized neutraavidin protein beads (Pierce, Rockford, IL) at 5C.
The beads were previously washed with the quench buffer. The biotin-
labeled subunit is bound to the beads and removed by centrifugation, while
the unlabeled subunit remains in the supernatant. Use of 100 mL of beads
ensured complete separation of the two subunits.
Deuterium-labeled protein in the supernatant was digested on ice with
5 mL of 1 mg/mL porcine pepsin in H2O for 5 min and analyzed by
HPLC-MS as described (24,27). Data for deuterium uptake were collected
using a LTQ-XL linear ion trap mass spectrometer. Additional data were
collected using a LTQ-FT-ICR mass spectrometer.
Peptide centroid masses were calculated using the software HXExpress
(28). Deuterium levels corrected for back exchange were calculated for
each peptide using the equation
D ¼ m m0%
m100% m0%  N; (1)
where D is the number of amide hydrogens exchanged with deuterium, m is
the centroid mass of the peptide at a given time point, m0% is the mass of
the undeuterated peptide, m100% is the mass of the fully deuterated
peptide, and N is the number of amide hydrogens in the peptide. For
peptides with double isotopic envelopes, the centroid mass was calculated
for the entire range including peaks at both high and low m/z. The number
of deuteria exchanged in unliganded RT (24) was subtracted from the
number exchanged in the RT-EFV complex. Significant differences in deu-
teria exchanged were determined by repeating the 5 s time point 10 times.Biophysical Journal 100(1) 144–153The average standard deviation for all peptides was 0.4 deuterium. Differ-
encesR1.2 deuteria exchanged (3 SD) were considered significant. Protein
solutions containing 84% and 97% p66/p51-EFV complex gave identical
results within error. Analysis of four repetitions of the complete H/D
exchange time course for each subunit indicates reproducibility of the
results.
A control experiment for nonspecific effects of efavirenz on the H/D
exchange behavior of RTwas performed. A concentrated solution of efavir-
enz in dimethylformamide (DMF) was added to RT heterodimer to a final
concentration of 50 mM efavirenz and 1.6% DMF. HXMS was measured
immediately after addition of efavirenz using an incubation time of 5 s in
D2O. Formation of the specific RT-EFV complex is slow (16). The t1/2
for efavirenz binding is ~15 min at the concentrations used here. At 5 s,
no differences were observed between RT solutions containing 1.6%
DMF with and without efavirenz.RESULTS
HXMS was performed and the measured deuterium uptake
of RT-EFV complex was compared with the previously
reported deuterium uptake of unliganded RT (24). Except-
ing the presence of efavirenz, experimental conditions
were identical. RT-EFV complexes were diluted into D2O,
samples were removed at various times, and the exchange
was quenched. Peptic fragments provided ~75% coverage
for both subunits. The HXMS data for the two subunits of
RT-EFV complex are consistent with the overall secondary
structure in the crystal structures (29,30) with the exception
of peptide 417–425 in p51 (Fig. 2).
Half of the exchangeable amide hydrogens in this peptide
are located in an a-helix in p51, and yet the peptide shows
no protection at even the shortest labeling times. Exchange
that occurs at early times (5 s) after dilution into D2O
primarily reflects solvent accessibility of the amide back-
bone; regions that are intrinsically unstructured and
solvent-exposed or that are in a rapid equilibrium that favors
an unfolded solvent-exposed form will undergo extensive
exchange within a few seconds. Differences in exchange
at 5 s in the presence and absence of ligand can therefore
reveal folding/unfolding that occurs in response to ligand
binding (31). Exchange at longer times (minutes to hours)
reflects the flexibility of secondary and tertiary structure.Efavirenz binding region
The consensus NNRTI binding pocket is formed by two
b-sheets, b6-b10-b9 and b12-b13-b14, in the palm and
Y318 at the thumb/connection junction of p66 as well as
residue E138 of p51 (32). Efavirenz makes contact with
14 residues in p66 and none in p51 (29,30,33). Peptides
88–109, 187–192, 210–231, 232–246, and 301–328 contain
12 of the 14 residues in the binding site; V179 and Y181 in
b-strand 9 aremissing coverage. All but one of these peptides
show significant reductions in H/D exchange in RT-EFV
complex. Peptide 187–192 is so rigid that it exchanges only
one amide hydrogen at long times in unliganded RT (24)
and less than one amide hydrogen in the complex.
FIGURE 2 Percent exchange of peptides in RT-EFV complex. (A) p66 and (B) p51 subunits. Gray and orange bars above sequence represent a-helices and
b-strands, with noted secondary structure labeled. Secondary structure represents the consensus of 1FK9 and 1IKW supplemented by the program STRIDE.
Colored arrows above sequence represent polymerase subdomains: (blue) fingers, (red) palm, (green), thumb, (orange) connection; and (magenta) RNase H
domain. Colored bars below sequence from top to bottom give exchange at 5, 60, 900, 3000, and 7200 s. Contact residues: (bold and underlined) dimer
interface, (blue) polymerase and RNase H primer grips, (green) polymerase active site, (tan) RNase H active site, and (red) efavirenz.
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tions in exchange at long times (Fig. 3 A); 88–109,
210–231, and 232–246 exchange 2–4 fewer amide hydro-
gens in RT-EFV complex compared to unliganded RT. As
in unliganded RT (24), peptide 232–246 undergoes slow
cooperative unfolding/refolding leading to EX1 exchange.
However, the rate of unfolding is dramatically slowed in
the presence of efavirenz. This peptide includes b-strands
13 and 14 of b12-b13-b14 that forms the lid of the binding
pocket. The EX1 exchange causes a double isotopic enve-
lope due to two slowly interconverting conformations in
solution, as discussed in the Introduction (34). Once the
unfolded state is sampled in solution, it becomes irreversibly
labeled with deuterium.
Fig. 4 A shows the mass spectra of the doubly charged ion
of peptide 232–246 at various times after dilution of
RT-EFV complex into D2O. The 5 s time point shows that
the folded population of b12-b13-b14 is the dominant
form in solution with ~80% of the molecules in the folded
conformation. By 8 h, 60% of the folded population still
remains, indicating that efavirenz locks the b-sheet in thefolded conformation in the majority of the complexes. At
the concentrations of RT and efavirenz used in the H/D
exchange experiments, the heterodimer is saturated with
efavirenz before and after dilution into D2O. Thus, RT-EFV
complex populates at least two conformations with either
a folded or unfolded b-sheet. The behavior of b12-b13-
b14 in RT-EFV complex is in stark contrast to the rapid
unfolding in unliganded RT, where the folded population
has entirely disappeared after 30 s (24). Ligand binding
has been shown before to slow the rate of unfolding
observed by HXMS (23). The dramatic effect on the unfold-
ing of b-strands 13 and 14, together with the decreased
exchange at long times in the four peptides containing 10
of 14 drug contact residues, indicate that efavirenz binding
stabilizes the entire efavirenz-binding region.Allosteric effects in p66
Fig. 3 shows differences in deuteria exchanged in RT-EFV
complex relative to unliganded RT (24) for the 10 of
26 peptides in p66 and the five of 21 peptides in p51 thatBiophysical Journal 100(1) 144–153
FIGURE 3 Difference in number of deuteria exchanged in RT-EFV
complex and unliganded RT. Differences calculated by subtracting the
exchange of unliganded RT (24) from the exchange of RT-EFV complex.
Differences are shown for (A) p66 and (B) p51 subunits for exchange at
(black) 5 s, (gray) 60 s, and (white) 3000 s. Only peptides with a difference
>1.2 deuteria are shown.
148 Seckler et al.show significant changes in deuterium uptake at early, inter-
mediate, or long times. Efavirenz contacts account for the
three peptides in the p66 palm discussed above: 88–109,
210–231, and 232–246. The remaining seven peptides in
the p66 thumb and connection and the RNase H domain
show altered deuterium uptake due to allosteric effects of
efavirenz binding (Fig. 3 A). The allosteric changes in p66
can be divided into three regions based on the effects of efa-
virenz on H/D exchange (Fig. 3 A; Table 1). The peptides in
these three allosteric regions are contiguous in the three-
dimensional structure of RT (Fig. 1 B).
Region-1 peptides exchange fewer deuteria at long times
in the presence of efavirenz: 257–282 in the thumb and
301–328 in the thumb/connection junction. Peptide
257–282 shows minor increases in exchange at early times,
but large decreases at long times. These decreases indicate
that the existing helices in the thumb, aH and aI, become
more rigid as a result of efavirenz binding (Fig. 2 A). Peptide
301–328 contains a single drug contact at Y318. As with
peptide 257–282, this peptide shows a large decrease inBiophysical Journal 100(1) 144–153exchange at long times. Additionally, there are modest
decreases at intermediate times. Although peptide 301–328
contains a drug contact residue, the fact that nine amide
hydrogens show reduced exchange indicates allosteric stabi-
lization of b-strands 15 and 16 and helix aJ (Fig. 2 A).
Region-2 peptides exchange fewer deuteria at interme-
diate and long times: 341–370 in the connection and
469–479 and 501–517 in the RNase H domain, indicating
stabilization of three a-helices, aK, aA0, and aB0, and two
b-strands, b17 and b18 (Fig. 2 A).
Region-3 peptides become slightly more flexible in RT-
EFV complex: 492–500 and 534–560 also in the RNase H
domain. This is the only region that is primarily destabilized
by efavirenz binding. Peptide 492–500 contains the seven-
residue b-strand 40 (Fig. 2 A). All seven amide hydrogens
are protected at all times in unliganded RT, and at early
and intermediate times in RT-EFV complex. However, the
increased exchange of three amide hydrogens at long times
indicates that efavirenz binding makes the five-strand
b-sheet b30-b20-b10-b40-b50 in the RNase H domain slightly
more flexible. Peptide 534–560 shows exchange of four
more amide hydrogens at 5 s, which indicates unfolding.
One crystal structure of RT-EFV complex contains the
entire C-terminal helix aE0 (Fig. 2 A), which spans 11 amino
acids (29). At early times in unliganded RT, peptide
534–560 has 11 protected amide hydrogens, dropping to
four amide hydrogens at intermediate and long times (24).
The RT-EFV complex has only seven amide hydrogens pro-
tected at early times, likewise dropping to four amide hydro-
gens at intermediate and long times. The early time data for
this peptide indicate that helix aE0 is shortened by four
amino acids in solution. Two of the four catalytic residues
in the RNase H active site are contained in the region-3
peptides, and another single residue lacking coverage is
adjacent to and possibly part of the putatively flexible
b-strand 10. Destabilization of secondary structure around
the active site residues may account for the constellation
of effects of efavirenz on RNase H activity (35).Allosteric effects in p51
Five peptides in the palm and thumb subdomains of
p51 show significant stabilization in RT-EFV complex
(Fig. 3 B; Table 1).
Region-4 peptides exchange fewer deuteria at intermediate
and long times in the presence of efavirenz: 88–109 and
210–231 in the palm, and 232–246 in the palm/thumb junc-
tion. Peptide 88–109 exchanges two fewer deuteria at long
times, implying modest stabilization of b-strand 6 and helix
aC due to efavirenz binding (Fig. 2 B). Peptide 210–231
exchanges approximately two fewer deuteria at all times,
indicating the formation of two stable hydrogen bonds in
RT-EFV complex. The crystal structures are missing electron
density in the latter half of this peptide, and no secondary
structure is reported for the first half in either the absence or
FIGURE 4 Fourier transform ion cyclotron reso-
nance (FT-ICR) mass spectra of peptide 232–246
in RT-EFV complex. (Upper) p66 and (lower)
p51 subunits after various incubation times in
D2O (vertical lines). The low and high m/z peaks
for both subunits are fit to (black) Gaussian distri-
butions. The (gray) envelope is the sum of these
two distributions. The percent unfolded for p51
subunit was calculated from the ratio of the areas
of the highm/z black envelope to the gray envelope
(bottom right panel).
TABLE 1 Allosteric peptides and functional residues
Function Peptides/residues Subunit
Efavirenz binding region 88–109, 210–231, 232–246 p66
Allosteric region 1 257–282, 301–328 p66
Allosteric region 2 341–370, 469–479, 501–517 p66
Allosteric region 3 492–500, 534–560 p66
Allosteric region 4 88–109, 210–231, 232–246 p51
Allosteric region 5 257–282, 301–328 p51
Polymerase active site D110, D185, D186 p66
Polymerase
primer grip
F227, L228, W229, M230,
G231, Y232, E233, L234
p66
RNase H active site D443, E478, D498, D549 p66
RNase H primer grip G359, A360, H361, T473,
N474, Q475, K476, Y501, I505
p66
K395, E396 p51
Allosteric Network in Reverse Transcriptase 149presence of efavirenz. Nevertheless, about seven and five
amide hydrogens are protected inRT-EFVcomplex and about
five and three are protected in unliganded RTat intermediate
and long times.
Surprisingly, peptide 232–246 in region 4 of p51 shows
EX1 exchange in RT-EFV complex (Fig. 4 B). In p51 of un-
liganded RT, this peptide is fully exchanged by 5 s. In p66,
this same peptide, which contains b-strands 13 and 14,
shows EX1 exchange in both the presence and absence of
efavirenz, but the rate of local cooperative unfolding is dras-
tically slowed in the presence of efavirenz, as described
above. Also in p66, this peptide is part of the NNRTI
binding pocket. Equilibrium dialysis studies of p66/p66
and p51/p51 homodimers showed that one efavirenz binds
per dimer in solution (16), consistent with the binding stoi-
chiometry in all the crystal structures of RT-NNRTI
complexes (11). Therefore, the EX1 exchange in Fig. 4 B
is not due to efavirenz binding to the p51 subunit in solution.
The double isotopic envelope in p51 was fitted to two
Gaussian distributions and the mass difference betweenthe centroids corresponds to a difference of four amide
hydrogens between the folded and unfolded peaks
(Fig. 4 B). In the crystal structures of RT-EFV complex
(29,30), this peptide contains helix aG with five exchange-
able amide hydrogens (Fig. 2 B); helix aG is absent inBiophysical Journal 100(1) 144–153
150 Seckler et al.unliganded RT. The EX1 behavior suggests helix aG
undergoes slow cooperative unfolding with a t1/2 of 2 h in
the presence of efavirenz. Formation of the small helix
aG in the presence of efavirenz shortens the linker connect-
ing the p51 thumb to the palm and could constrain the thumb
motion, which would change the interaction between the
p51 thumb and the RNase H domain. The tighter subunit
interactions would stabilize helices aH, aI, and aJ in region
5 (Fig. 2 B). This scenario is consistent with the large
enhancement of RT dimerization by efavirenz (25,36).
Region-5 peptides exchange fewer amide hydrogens at
long times in RT-EFV complex: 257–282 in the thumb
and 301–328 in the thumb/connection junction. At early
times, peptide 257–282 exchanges two more deuteria in
RT-EFV complex, which suggests slight unfolding upon
efavirenz binding. At long times, this peptide exchanges
four fewer amide hydrogens, consistent with stabilization
of helix aH or aI (Fig. 2 B). Peptide 301–328 shows large
decreases in exchange at intermediate and long times, indi-
cating substantial stabilization of helix aJ. Region 5 is
spatially adjacent to region 3 in the RNase H domain, and
intersubunit allosteric effects may propagate through
contacts between the p51 thumb and the RNase H domain.DISCUSSION
Efavirenz binding rigidifies the structure of RT. In the
absence of inhibitor, the structure in the palm, thumb, and
connection subdomains of both subunits as well as the
RNase H domain is significantly more flexible than
expected from crystal structures (24). The allosterically
coupled regions identified here, which extend throughout
the heterodimer, represent a subset of these more flexible
peptides (Fig. 1 B). The large-scale rigidification in the pres-
ence of efavirenz is circumstantial evidence that the flexi-
bility observed in the absence of inhibitor is critical for
normal function of the enzyme. The multiple conforma-
tional states observed in crystallographic studies also
provide circumstantial evidence for the importance of
structural flexibility in the activity of RT and other polymer-
ases (2,37,38). Although the p51 subunit is essential for RT
function, it contains only one residue in the consensus
NNRTI binding pocket (0 in the efavirenz binding site)
and two residues in the RNase H primer grip (3,32). This,
combined with the fact that p51 undergoes miniscule struc-
tural changes upon ligand binding, has led to the conjecture
that p51 plays only a structural role. The HXMS results indi-
cate otherwise. Figs. 1 B and 3 B show that two regions of
p51 are part of the allosteric network.
How do the observed changes in flexibility correlate with
the proposed models for NNRTI inhibition? The arthritic
thumb model states that inhibitor binding restricts the
motions of the thumb subdomain. HXMS results show
that efavirenz binding rigidifies secondary structure in
region 1 of the allosteric network, indicating that helicesBiophysical Journal 100(1) 144–153aH, aI, and aJ, which form the core of the p66 thumb,
can no longer flex.
In the primer grip model, NNRTI binding distorts the resi-
dues which make up the polymerase primer grip, preventing
proper positioning of the primer 30-end in the polymerase
active site. Peptides covering the efavirenz binding region
include not only the drug contact residues, but also the poly-
merase primer grip (residues 227–235). The polymerase
primer grip spans two peptides 210–231 and 232–246.
The latter peptide, containing b-strands 13 and 14,
undergoes slow cooperative unfolding in the absence of
inhibitor, but efavirenz binding dramatically stabilizes
b12-b13-b14. Peptide 210–231 exchanges two fewer deute-
ria at long times, implying that b-strand 12, which forms the
other half of the polymerase primer grip, is also stabilized.
Together these results clearly indicate that the flexibility
of the polymerase primer grip is perturbed by efavirenz
binding.
The active site distortion model asserts that NNRTI
binding restricts conformational changes in the YMDD
loop necessary for DNA polymerization. Peptide 183–187
covers the YMDD loop, which contains two of the three
aspartate residues in the catalytic triad; the third aspartate
of the triad is in peptide 110–115. H/D exchange rates of
both peptides are similar in the presence and absence of
efavirenz. The peptide containing the YMDD loop, like the
adjacent peptide 187–192, is rigid, exchanging less than
one amide hydrogen at long times in unliganded RT and at
most one amide hydrogen in RT-EFV complex. The central
b-strand 10 of b6-b10-b9 spans the rigid peptides 183–187
and 187–192, suggesting that this b-sheet is stable in both
free and bound RT. The biochemical data and proposed inhi-
bition mechanisms focus on the p66 polymerase domain,
whereas the HXMS results point to a view of NNRTI action
in which inhibition involves global suppression of protein
dynamics in multiple domains and both subunits.
In contrast to the effects of NNRTIs on polymerase
activity, the effects of inhibitors on RNase H activity have
been less extensively studied. Efavirenz enhances the poly-
merase-dependent RNase H activity and inhibits the poly-
merase-independent activity (39,40). The RNase H
inhibitor dihydroxy benzoyl napthyl hydrazone (DHBNH)
provides another example of allosteric communication
between the polymerase and RNase H domains (41).
DHBNH binds between the NNRTI binding pocket and
the polymerase active site, >50 A˚ from the RNase H active
site. However, this inhibitor has little effect on polymerase
activity. HXMS indicates that four of the five peptides in
the RNase H domain undergo changes in flexibility upon
EFV binding (Fig. 3 A). These peptides include nine of 11
residues in the RNase H primer grip, and two of four resi-
dues in the RNase H active site (1,3). Efavirenz binding
stabilizes the RNase H primer grip and loosens the RNase
H active site slightly. Although dramatic, the functional
significance of these allosteric changes is not obvious.
Allosteric Network in Reverse Transcriptase 151One possibility is that stabilization of the RNase H primer
grip residues has differential effects on polymerase-depen-
dent and -independent binding modes. Interestingly, in
p66 monomer complexed with efavirenz, the RNase H
domain does not undergo allosteric changes in regions 2
and 3 (42), indicating an active role for the p51 subunit in
communication between the polymerase and RNase H
domains of the p66 subunit.
The long-range effects of efavirenz binding identified by
H/D exchange have implications for NNRTI resistance in
RT. Most of the common clinical NNRTI resistance muta-
tions, such as K103N and Y181C, are located near or in
the NNRTI binding pocket. More recently, drug resistance
mutations located in the connection and RNase H domain
have been identified in patient populations (43). In partic-
ular, mutations N348I and Q509L confer resistance to
some NNRTIs both alone and in combination with NRTI
resistance mutations. It is puzzling how these mutations
confer NNRTI resistance, given their locations remote
from the binding pocket. Both mutations are located in
region 2 of the allosteric network, whose conformational
dynamics are altered by efavirenz binding. If the effects of
NNRTI binding can propagate to these remote regions, as
the HXMS data clearly demonstrate, then it is possible
that mutational perturbations in these regions can propagate
to the NNRTI binding site (as well as elsewhere in the
allosteric network). Such bidirectional allosteric coupling
has been observed in other proteins such as integrins and
a2A/D adrenoceptors (44,45).
Ligands that preferentially bind to the folded state will
stabilize a protein against unfolding. If a protein folds/
unfolds as a single cooperative unit, then it is clear that
ligand binding will stabilize the entire structure including
regions distant from the binding site. Although this mecha-
nism may account for the reduced exchange in the p66 poly-
merase domain, it cannot explain all of the long-range
effects of efavirenz binding on RT. RT contains multiple
cooperative folding units. For example, the isolated RNase
H domain can be expressed as a folded and functional
protein (46,47). Additionally, monomeric forms of the p66
and p51 subunits are folded in solution and bind efavirenz
(16). Therefore some of the long-range alterations in H/D
exchange induced by efavirenz must involve allosteric
coupling between cooperative domains (48).
Classical studies of allostery emphasized discrete confor-
mational changes, but it is now appreciated that allosteric
communication can also occur through changes in structural
dynamics (19). One view states that allostery originates in
the ligand-induced stabilization of the residues around the
binding site (20). This stabilization propagates by reducing
the mobility of amino-acid side chains and amide backbone,
forming numerous pathways through the protein. It eventu-
ally reaches other sites, either activating or inhibiting them.
According to this model, upon efavirenz binding in the
pocket, each region of the allosteric network would stabilizeor destabilize contiguous regions, mechanically propagating
the effects of binding throughout the heterodimer.
Alternately, an ensemble-based approach has been used to
demonstrate energetic coupling of remote regions of a protein
(21,49). In this model, the energy propagates through
changes in the distribution of intra- and intermolecular inter-
actions, including solvent, rather than by discrete pathways.
In the case of RT, the subensemble with stabilized efavirenz
binding and allosteric regions (Fig. 1 B) represents the
protein population that binds efavirenz. This subensemble
is sparsely populated in the absence of efavirenz, but shifts
to the dominant population in RT-EFV complex. This picture
is consistent with recent studies suggesting that RT binds
NNRTIs by a conformational selection mechanism (16,17).
For efficient propagation of binding effects to distant
regions, the ensemble-based approach predicts that the
binding site must possess a dual character, including both
stable and unstable regions (50). The NNRTI binding pocket
is not present in crystal structures of RT in the absence of
NNRTIs (2). Of the two b-sheets that form the efavirenz
binding site, HXMS data show that b6-b10-b9 is almost
completely stable, whereas b12-b13-b14 is quite unstable
and rapidly samples an unfolded conformation in the
absence of NNRTIs. Binding of efavirenz shifts the confor-
mational ensemble of RT to a population in which b12-b13-
b14 is greatly stabilized. This redistribution of the ensemble
affects the efavirenz binding region as well as regions 1–5 of
the allosteric network. Efavirenz binding to RT may there-
fore represent a particularly dramatic example of binding
site stabilization coupled to allostery.CONCLUSIONS
The HXMS studies of RT-EFV complex reveal an extended
network of allosterically coupled sites that includes the
NNRTI binding pocket, the p66 thumb and connection,
and the RNase H domain, as well as the p51 palm and
thumb. This network suggests a possible mechanism by
which efavirenz binding in the NNRTI binding pocket might
alter the function of both the polymerase active site 10 A˚
away and the RNase H active site 50 A˚ away. Moreover, it
suggests an expanded view of inhibition, in which inhibitor
binding rigidifies multiple regions of RT, encompassing
regions beyond the p66 polymerase domain. Our results
support both the arthritic thumb and primer grip models of
inhibition, but incorporate an allosteric population shift
from the flexible unliganded ensemble to a more rigid efa-
virenz-bound ensemble. The HXMS results reveal five
regions in p66 and p51 which together form an extended
allosterically coupled network. These allosteric regions are
potential new drug targets (51).
We are grateful to Kathryn J. Howard for preparation of protein samples.
This work was supported by National Institutes of Health grant No.
GM071267.Biophysical Journal 100(1) 144–153
152 Seckler et al.REFERENCES
1. Jacobo-Molina, A., J. Ding, ., E. Arnold. 1993. Crystal structure of
human immunodeficiency virus type 1 reverse transcriptase complexed
with double-stranded DNA at 3.0 A˚ resolution shows bent DNA. Proc.
Natl. Acad. Sci. USA. 90:6320–6324.
2. Sarafianos, S. G., B. Marchand, ., E. Arnold. 2009. Structure and
function of HIV-1 reverse transcriptase: molecular mechanisms of
polymerization and inhibition. J. Mol. Biol. 385:693–713.
3. Sarafianos, S.G., K.Das,., E. Arnold. 2001.Crystal structure ofHIV-1
reverse transcriptase in complex with a polypurine tract RNA:DNA.
EMBO J. 20:1449–1461.
4. Shen, L., S. Peterson, ., R. F. Siliciano. 2008. Dose-response curve
slope sets class-specific limits on inhibitory potential of anti-HIV
drugs. Nat. Med. 14:762–766.
5. Abbondanzieri, E. A., G. Bokinsky, ., X. Zhuang. 2008. Dynamic
binding orientations direct activity of HIV reverse transcriptase.
Nature. 453:184–189.
6. Liu, S., E. A. Abbondanzieri, ., X. Zhuang. 2008. Slide into action:
dynamic shuttling of HIV reverse transcriptase on nucleic acid
substrates. Science. 322:1092–1097.
7. Figueiredo, A., K. L. Moore, ., G. Tachedjian. 2006. Potent nonnu-
cleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS
Pathog. 2:e119.
8. Kohlstaedt, L. A., J. Wang,., T. A. Steitz. 1992. Crystal structure at
3.5 A˚ resolution of HIV-1 reverse transcriptase complexed with an
inhibitor. Science. 256:1783–1790.
9. Hsiou, Y., J. Ding,., E. Arnold. 1996. Structure of unliganded HIV-1
reverse transcriptase at 2.7 A˚ resolution: implications of conforma-
tional changes for polymerization and inhibition mechanisms. Struc-
ture. 4:853–860.
10. Rodgers, D. W., S. J. Gamblin,., S. C. Harrison. 1995. The structure
of unliganded reverse transcriptase from the human immunodeficiency
virus type 1. Proc. Natl. Acad. Sci. USA. 92:1222–1226.
11. Ren, J., and D. K. Stammers. 2008. Structural basis for drug resistance
mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Virus Res. 134:157–170.
12. Ivetac, A., and J. A. McCammon. 2009. Elucidating the inhibition
mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors
through multicopy molecular dynamics simulations. J. Mol. Biol.
388:644–658.
13. Shen, L., J. Shen, ., H. Jiang. 2003. Steered molecular dynamics
simulation on the binding of NNRTI to HIV-1 RT. Biophys. J.
84:3547–3563.
14. Temiz, N. A., and I. Bahar. 2002. Inhibitor binding alters the directions
of domain motions in HIV-1 reverse transcriptase. Proteins Struct.
Funct. Bioinf. 49:61–70.
15. Zhou, Z., M. Madrid,., J. D. Madura. 2005. Effect of a bound non-
nucleoside RT inhibitor on the dynamics of wild-type and mutant
HIV-1 reverse transcriptase. J. Am. Chem. Soc. 127:17253–17260.
16. Braz, V. A., L. A. Holladay, and M. D. Barkley. 2010. Efavirenz
binding to HIV-1 reverse transcriptase monomers and dimers.
Biochemistry. 49:601–610.
17. Geitmann, M., T. Unge, and U. H. Danielson. 2006. Biosensor-based
kinetic characterization of the interaction between HIV-1 reverse tran-
scriptase and non-nucleoside inhibitors. J. Med. Chem. 49:2367–2374.
18. Weikl, T. R., and C. von Deuster. 2009. Selected-fit versus induced-fit
protein binding: kinetic differences and mutational analysis. Proteins
Struct. Funct. Bioinf. 75:104–110.
19. Tsai, C.-J., A. del Sol, and R. Nussinov. 2008. Allostery: absence of
a change in shape does not imply that allostery is not at play. J. Mol.
Biol. 378:1–11.
20. del Sol, A., C.-J. Tsai,., R. Nussinov. 2009. The origin of allosteric
functional modulation: multiple pre-existing pathways. Structure.
17:1042–1050.Biophysical Journal 100(1) 144–15321. Liu, T., S. T. Whitten, and V. J. Hilser. 2006. Ensemble-based signa-
tures of energy propagation in proteins: a new view of an old phenom-
enon. Proteins Struct. Funct. Bioinf. 62:728–738.
22. Brier, S., and J. R. Engen. 2008. Hydrogen exchange mass spectrom-
etry: principles and capabilities. In Mass Spectrometry Analysis for
Protein-Protein Interactions and Dynamics. M. Chance, editor. Wiley,
Hoboken, NJ. 11–43.
23. Engen, J. R., T. E. Smithgall,., D. L. Smith. 1997. Identification and
localization of slow, natural, cooperative unfolding in the hematopoi-
etic cell kinase SH3 domain by amide hydrogen exchange and mass
spectrometry. Biochemistry. 36:14384–14391.
24. Seckler, J. M., K. J. Howard,., P. L. Wintrode. 2009. Solution struc-
tural dynamics of HIV-1 reverse transcriptase heterodimer. Biochem-
istry. 48:7646–7655.
25. Venezia, C. F., K. J. Howard,., M. D. Barkley. 2006. Effects of efa-
virenz binding on the subunit equilibria of HIV-1 reverse transcriptase.
Biochemistry. 45:2779–2789.
26. Tsutsui, Y., L. Liu, ., P. L. Wintrode. 2006. The conformational
dynamics of a metastable serpin studied by hydrogen exchange and
mass spectrometry. Biochemistry. 45:6561–6569.
27. Zhang, Z., and D. L. Smith. 1993. Determination of amide hydrogen
exchange by mass spectrometry: a new tool for protein structure eluci-
dation. Protein Sci. 2:522–531.
28. Weis, D. D., J. R. Engen, and I. J. Kass. 2006. Semi-automated data
processing of hydrogen exchange mass spectra using HX-Express. J.
Am. Soc. Mass Spectrom. 17:1700–1703.
29. Lindberg, J., S. Sigurdsson,., T. Unge. 2002. Structural basis for the
inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721
towards the HIV-1 RT K103N mutant. Eur. J. Biochem. 269:1670–
1677.
30. Ren, J., J. Milton, ., D. K. Stammers. 2000. Structural basis for the
resilience of efavirenz (DMP-266) to drug resistance mutations in
HIV-1 reverse transcriptase. Structure. 8:1089–1094.
31. Tsutsui, Y., and P. L. Wintrode. 2007. Hydrogen/deuterium exchange-
mass spectrometry: a powerful tool for probing protein structure,
dynamics and interactions. Curr. Med. Chem. 14:2344–2358.
32. Das, K., P. J. Lewi,., E. Arnold. 2005. Crystallography and the design
of anti-AIDS drugs: conformational flexibility and positional adapt-
ability are important in the design of non-nucleoside HIV-1 reverse
transcriptase inhibitors. Prog. Biophys. Mol. Biol. 88:209–231.
33. Sobolev, V., A. Sorokine, ., M. Edelman. 1999. Automated analysis
of interatomic contacts in proteins. Bioinformatics. 15:327–332.
34. Deng, Y., and D. L. Smith. 1998. Identification of unfolding domains in
large proteins by their unfolding rates. Biochemistry. 37:6256–6262.
35. Sluis-Cremer, N., and G. Tachedjian. 2008. Mechanisms of inhibition
of HIV replication by non-nucleoside reverse transcriptase inhibitors.
Virus Res. 134:147–156.
36. Tachedjian, G., M. Orlova,., S. P. Goff. 2001. Nonnucleoside reverse
transcriptase inhibitors are chemical enhancers of dimerization of the
HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA.
98:7188–7193.
37. Steitz, T. A. 2006. Visualizing polynucleotide polymerase machines at
work. EMBO J. 25:3458–3468.
38. Svetlov, V., and E. Nudler. 2009. Macromolecular micromovements:
how RNA polymerase translocates. Curr. Opin. Struct. Biol. 19:
701–707.
39. Hang, J. Q., Y. Li, ., K. Klumpp. 2007. Substrate-dependent inhibi-
tion or stimulation of HIV RNase H activity by non-nucleoside reverse
transcriptase inhibitors (NNRTIs). Biochem. Biophys. Res. Commun.
352:341–350.
40. Radzio, J., and N. Sluis-Cremer. 2008. Efavirenz accelerates HIV-1
reverse transcriptase ribonuclease H cleavage, leading to diminished
zidovudine excision. Mol. Pharmacol. 73:601–606.
41. Himmel, D. M., S. G. Sarafianos, ., E. Arnold. 2006. HIV-1 reverse
transcriptase structure with RNase H inhibitor dihydroxy benzoyl
napthyl hydrazone bound at a novel site. ACS Chem. Biol. 1:702–712.
Allosteric Network in Reverse Transcriptase 15342. Braz, V. A., M. D. Barkley,., P. L. Wintrode. 2010. Efavirenz binding
site in HIV-1 reverse transcriptase monomers. Biochemistry. 49:10565–
10573.
43. Ehteshami, M., and M. Go¨tte. 2008. Effects of mutations in the connec-
tion and RNase H domains of HIV-1 reverse transcriptase on drug
susceptibility. AIDS Rev. 10:224–235.
44. Hynes, R. O. 2002. Integrins: bidirectional, allosteric signaling
machines. Cell. 110:673–687.
45. Tian, W.-N., D. D. Miller, and R. C. Deth. 2000. Bidirectional allosteric
effects of agonists and GTP at a2A/D-adrenoceptors. J. Pharmacol. Exp.
Ther. 292:664–671.
46. Pari, K., G. A. Mueller,., R. E. London. 2003. Solution structure of
the RNase H domain of the HIV-1 reverse transcriptase in the presence
of magnesium. Biochemistry. 42:639–650.47. Smith, J. S., and M. J. Roth. 1993. Purification and characterization of
an active human immunodeficiency virus type 1 RNase H domain.
J. Virol. 67:4037–4049.
48. Luque, I., S. A. Leavitt, and E. Freire. 2002. The linkage between
protein folding and functional cooperativity: two sides of the same
coin? Annu. Rev. Biophys. Biomol. Struct. 31:235–256.
49. Pan, H., J. C. Lee, and V. J. Hilser. 2000. Binding sites in Escherichia
coli dihydrofolate reductase communicate by modulating the confor-
mational ensemble. Proc. Natl. Acad. Sci. USA. 97:12020–12025.
50. Freire, E. 1999. The propagation of binding interactions to remote sites
in proteins: analysis of the binding of the monoclonal antibody D1.3 to
lysozyme. Proc. Natl. Acad. Sci. USA. 96:10118–10122.
51. Goodey, N. M., and S. J. Benkovic. 2008. Allosteric regulation and
catalysis emerge via a common route. Nat. Chem. Biol. 4:474–482.
52. DeLano, W. L. 2002. The PyMOLMolecular Graphic System. DeLano
Scientific, San Carlos, CA. http://www.pymol.org.Biophysical Journal 100(1) 144–153
